News Focus
News Focus
icon url

alwayswatching1

03/03/26 12:43 PM

#446415 RE: SovereignNinja5 #446414

This might be one of the most important well stated post we have had on iHub in a very long time. Thank you SN5
icon url

TastyTheElf

03/03/26 1:06 PM

#446416 RE: SovereignNinja5 #446414

I still don't understand why, if this is such a seismic development for Amarin, management has said literally nothing about it.

Is there a reason to stay utterly silent on this. Prior management certainly talked about the combo pill...

Incidentally, I checked the Recordati agreement -- it appears to cover any new "formulation"...

1.48“Licensed Product” means the pharmaceutical product marketed under the trade name Vazkepa® and other associated Trademarks containing or comprising the compound Icosapent ethyl in any present or future finished form presentations (including all dosage forms, formulations, dosage strengths and packaging configurations).

icon url

JRoon71

03/03/26 1:15 PM

#446418 RE: SovereignNinja5 #446414

I have been hoping for the 505(b)(2) pathway, but I don't know that there is any consensus on whether they can follow that pathway or not.

I tend to agree with you, that they can. I just wish we could get some more color on how/when/if they plan to execute this.